Cargando…
Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
Entecavir requires long-term administration. Pegylated interferon (PEG-IFN) therapy leads to significant reduction of hepatitis B surface antigen (HBs Ag) levels. This study aimed to assess the safety and efficacy of adding PEG-IFN-α-2a to entecavir toward cessation of entecavir. A total of 23 patie...
Autores principales: | Tamai, Hideyuki, Ida, Yoshiyuki, Shingaki, Naoki, Shimizu, Ryo, Fukatsu, Kazuhiro, Itonaga, Masahiro, Yoshida, Takeichi, Maeda, Yoshimasa, Moribata, Kosaku, Maekita, Takao, Iguchi, Mikitaka, Kato, Jun, Kitano, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405394/ https://www.ncbi.nlm.nih.gov/pubmed/28487770 http://dx.doi.org/10.1155/2017/2093847 |
Ejemplares similares
-
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2017) -
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2016) -
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
por: Taki, Shinya, et al.
Publicado: (2018) -
Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence
por: Shimizu, Ryo, et al.
Publicado: (2021) -
Prediction of a Null Response to Pegylated Interferon α-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
por: Wada, Yuki, et al.
Publicado: (2014)